| Literature DB >> 29967624 |
Abstract
Agnathans (lamprey and hagfish) are a group of primitive jawless fish. Jawed vertebrates possess adaptive immunity including immunoglobulins, while agnathans lack immunoglobulins but have alternative adaptive immunity in which variable lymphocyte receptors (VLRs) function as antibodies. The complement system consists of many proteins involved in the elimination of pathogens. In mammals, it is activated via the three different pathways, resulting in the generation of C3b followed by the lytic pathway. Complement components including C3, mannose-binding lectin (MBL), and MBL-associated serine proteases (MASP) of the lectin pathway and factor B of the alternative pathway have been identified from lamprey and/or hagfish, while lytic pathway components have not been identified. In mammals, C1q binds to IgM/IgG-antigen complexes and activates the classical pathway in association with C1r and C1s. Lamprey also has C1q (LC1q), but its function differs from that of mammalian C1q. LC1q acts as a lectin and activates C3 in association with MASP via the lectin pathway. Furthermore, LC1q may interact with a secreted type of VLR (VLRB) in complex with antigens and mediate activation of C3, potentially via MASP, leading to cytolysis. Cytolysis is mediated by a newly identified serum protein named lamprey pore-forming protein (LPFP). In conclusion, lamprey has a complement activation pathway, which could be regarded as the classical pathway and also has a cytolytic system that is distinct from the mammalian lytic pathway. Thus, it appears that the complement system of agnathans is very unique and may have developed independently from jawed vertebrates.Entities:
Keywords: C1q; agnathans; complement; lamprey; variable lymphocyte receptors
Year: 2018 PMID: 29967624 PMCID: PMC6015906 DOI: 10.3389/fimmu.2018.01405
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1The complement system of mammals and agnathans. (A) Mammalian complement system. Lectin pathway: the lectin pathway is initiated by the binding of serum collagenous lectins [mannose-binding lectin (MBL), ficolin or CL-LK] to carbohydrates on pathogens. The lectins are complexed with MASP-1 and MASP-2. MASP-1 is auto-activated, and in turn, activates MASP-2. Activated MASP-2 cleaves C4 and C2 to generate a bimolecular C4bC2a complex. MASP-1 is also able to cleave C2. The C4bC2a complex acts as a C3 convertase that cleaves C3 into C3a and C3b. The trimolecular complex C4bC2aC3b acts as a C5 convertase cleaving C5 into C5a and C5b. Classical pathway: the classical pathway is initiated by the binding of C1 to antigen-antibody (IgG and IgM) complexes through C1q. C1r is auto-activated, and in turn activates C1s. Activated C1s cleaves C4 and C2 to generate a C3 convertase C4bC2a, followed by C3 and C5 activation as is the case with the lectin pathway. Alternative pathway: Factor B bound to C3b on the surface of pathogens is cleaved by factor D to generate Bb. The bimolecular C3bBb complex acts as a C3 convertase. C3b forms a trimolecular complex with C3bBb, which acts as a C5 convertase. After C5b is generated via the three activation pathways, C5b, C6, C7, C8, and C9 are assembled sequentially, leading to the polymerization of C9 (lytic pathway). (B) Agnathan complement system. Lectin pathway: MBL forms a complex with MBL-associated serine proteases (MASP) (MASP-1, MASP-A, and MASP-B). C1q forms a complex with MASP-A and possibly with MASP-1 and MASP-B. Upon binding of the MBL-MASP or C1q-MASP complexes to carbohydrates on pathogens, MASP changes from the unactivated form to the active form. As a result, activated MASP cleaves C3 into C3a and C3b. Which MASP is responsible for C3 cleavage is unknown. Classical pathway: VLRB, which forms a pentamer or tetramer of dimers, acts as an antibody and specifically binds to the antigens on pathogens. C3 is activated potentially via MASP associated with C1q that is bound to VLRB. Complement activation by C1q-MASP and VLRB leads to the polymerization of lamprey pore-forming protein (LPFP), resulting in the cytolysis of pathogens. Factors and mechanisms between the generation of C3b and the polymerization of LPFP are unknown. Alternative pathway: Although factor D has not been identified in agnathans, it is possible that C3 is activated by the C3bBb complex on pathogens as is the case with the mammalian alternative pathway. It remains unclear whether complement activation via the lectin and alternative pathways leads to LPFP-mediated cytotoxicity. Red and black arrows indicate proteolysis and reaction sequence, respectively.
Figure 2Structure of agnathan complement components. (A) Schematic representation of the primary structure of lamprey C3 (LC3), human C3 (HuC3), and human C4 (HuC4). The β − α and α − γ processing sites are shown in red and blue, respectively. These proteins are produced as a single polypeptide. After processing, the mature proteins with disulfide-bridged three polypeptides (α, β, and γ chains) or with disulfide-bridged two polypeptides (α and β chains) are produced. The thioester region is shown in yellow. (B) Domain structure of lamprey and human MASP. MASP consists of six domains, C1r/C1s/Uegf/bone morphogenetic protein (CUB) 1, epidermal growth factor, CUB 2, complement control protein (CCP) 1, CCP2 and serine protease domain. An unactivated form of MASP with a single polypeptide chain changes to an active form of MASP with two polypeptide chains linked by a disulfide bond by cleavage of a peptide bond (arrow). Codon for the serine residue essential for the catalytic activity in the protease domain of each MASP is listed. Substrates for each MASP are also summarized (n.d, not determined). LMASP-1, lamprey MASP-1; LMASP-A, lamprey MASP-A; LMASP-B, lamprey MASP-B; HuMASP-1, human MASP-1; HMASP-2, human MASP-2; HMASP-3, human MASP-3. (C) Domain structure of lamprey and human C1q. C1q consists of both collagen-like and gC1q domains. The number of Gly-Xaa-Yaa repeats of each C1q is listed. One cysteine residue is present in the N-terminal region for LC1q, L-C1qDC-1, HuC1qA, HuC1qB, and HuC1qC, while two cysteine residues for HC1q. HuC1qA, human C1qA chain; HuC1qB, human C1qB chain; HuC1qC, human C1qC chain.